Return to Listing

4 result(s) for

PI Name Protocol # Title
Zahi Mitri IRB00006256 I-SPY 2 TRIAL: Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2
Zahi Mitri STUDY00018504 A Phase II, Open Label, Study of Olaparib and Durvalumab in Patients with Metastatic Triple Negative Breast Cancer
Charles Lopez STUDY00019211 A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients with Pancreatic Ductal Adenocarcinoma
Adel Kardosh STUDY00021972 A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080